Six people whose rheumatoid arthritis had defeated as many as eight previous drugs received a single infusion of a therapy built for blood cancer, and every one of them got better. Three of them stopped taking rheumatoid arthritis medication entirely and stayed off it through the end of follow-up.
That is the headline result from the first clinical trial to test CD19 CAR T-cell therapy in rheumatoid arthritis, run by researchers at Charité in Berlin and published in Nature Medicine. It is a real finding, and it deserves to be reported carefully, because six patients is six patients.
For the more than a million American adults living with rheumatoid arthritis, the meaningful part is not that a cure has arrived. It has not. The meaningful part is that a treatment strategy aimed at resetting the immune system, rather than suppressing it indefinitely, produced measurable off-medication remission in people for whom nothing else had worked.
The Trial and Its Six Participants
The phase 1 portion of the COMPARE trial enrolled three men and three women, ages 31 to 69, with severe treatment-refractory rheumatoid arthritis. All were positive for anti-citrullinated protein antibodies, a marker of the seropositive form of the disease. Each had cycled through up to eight targeted or biologic therapies over roughly a decade without adequate control.
Participants stopped all disease-modifying antirheumatic drugs, underwent standard lymphodepletion, and received one infusion of mivocabtagene autoleucel, a CD19 CAR T-cell product made from each patient's own cells. They were followed for 36 to 52 weeks.
Gerhard Krönke, one of the Charité researchers behind the work, said of the results that "disease activity decreased markedly in all six patients." Three were in sustained remission without any rheumatoid arthritis medication by the end of follow-up.
Responses varied. Not everyone reached drug-free remission, and the researchers reported differences among participants in how deeply and how durably they responded.
A Reset Rather Than Suppression
Rheumatoid arthritis medication works by damping inflammation or blocking immune signals. It controls the disease while a patient keeps taking it. Stop, and the disease usually returns. Off-drug remission has been rare.
The CAR T approach starts somewhere else. A patient's own T cells are engineered to recognize CD19, a marker on B cells, including the B cells producing the autoantibodies that drive seropositive rheumatoid arthritis. The engineered cells hunt those B cells down, and the trial's imaging suggested they reach them inside inflamed tissue rather than only in the bloodstream.
When B cells later return, they come back predominantly as naive cells rather than the autoreactive population that was cleared. That is the reset the researchers describe, and it is the same mechanism behind earlier reports in lupus and systemic sclerosis.
Imaging from the trial showed inflammatory foci around the knee joints of a participant that were no longer detectable several months after infusion, alongside reduced swelling and pain and improved mobility.
The Limits That Come with Six Patients
This is a phase 1 trial. Its purpose was safety and preliminary signal, not proof of benefit, and its design carries limits that belong up front rather than buried.
There was no control group. Six participants are too few to estimate how often the therapy works or in whom. Follow-up ran under a year, which cannot answer whether remission lasts, and relapse after CAR T therapy has already been documented in other autoimmune conditions. The trial enrolled only seropositive patients, so it says nothing about the substantial share of people with rheumatoid arthritis who are seronegative.
Safety was described as manageable but not trivial. Cytokine release syndrome occurred at mild to moderate levels, and no immune effector cell-associated neurotoxicity syndrome was reported. The procedure still requires lymphodepletion chemotherapy before infusion, and deep B-cell depletion carries infection risk while the immune system rebuilds.
The findings were first presented at a European rheumatology congress several weeks before the full publication, which is worth noting because congress abstracts and peer-reviewed papers sometimes differ in the detail they report. The trial's second phase will enroll ten additional patients and compare the cell therapy against rituximab, an approved drug that also targets B cells. Larger controlled trials will decide whether this becomes a treatment or remains an interesting early result in a small group of patients.
Realistic Expectations for Patients Living with RA
Nobody with rheumatoid arthritis can get this treatment outside a clinical trial today. It is not approved for any autoimmune indication in the United States, and it will not be for years, if ever.
The practical implication for patients is narrower and more immediate. Anyone whose disease remains poorly controlled after multiple biologic or targeted therapies is a candidate for a referral conversation with a rheumatologist about trial enrollment, not about this specific product but about the growing set of cell therapy studies in autoimmune disease. Academic medical centers in Boston, Philadelphia, New York City, Chicago, and other research hubs are the realistic starting point. Genetic work is opening similar avenues in related conditions, as MedicalDaily reported on the largest genetic study of fibromyalgia.
No one should stop or reduce a prescribed rheumatoid arthritis medication based on this study. The participants stopped their drugs under close supervision as part of a trial protocol with rescue plans in place. Doing so independently risks a flare and joint damage that may not be reversible.
Cost is worth naming even though it is not yet a decision point. CAR T therapies in cancer carry list prices in the hundreds of thousands of dollars and require treatment at specialized centers with the staffing to manage cytokine release syndrome. If this approach reaches approval in autoimmune disease, access and coverage will be substantial obstacles, and that conversation has barely started.
The signals worth watching next are the phase 2 COMPARE data, relapse rates as follow-up lengthens across autoimmune CAR T programs, and whether any regulator accepts an autoimmune indication. MedicalDaily will track those.
Key Questions Answered
What did the study find? In six people with severe treatment-refractory rheumatoid arthritis, a single CD19 CAR T-cell infusion markedly reduced disease activity in all participants, and three reached sustained remission without rheumatoid arthritis medication during follow-up of up to one year.
How large and how rigorous was it? Six patients, phase 1, no control group, followed 36 to 52 weeks. It was designed to assess safety and early signals, not to prove effectiveness.
How is this different from current treatment? Standard medication suppresses inflammation for as long as a patient keeps taking it. This approach clears the B cells producing disease-driving autoantibodies, after which B cells return predominantly as naive cells.
Were there side effects? Cytokine release syndrome occurred at mild to moderate levels, with no neurotoxicity syndrome reported. The procedure requires lymphodepletion chemotherapy beforehand, and deep B-cell depletion carries infection risk.
Does this apply to everyone with rheumatoid arthritis? No. All six participants had seropositive disease, and the trial enrolled only people whose disease had failed multiple prior therapies.
Can patients get this treatment now? No. It is not approved for autoimmune disease and is available only within clinical trials.
Should anyone change their medication because of this? No. Trial participants stopped drugs under supervision within a protocol. Stopping independently risks a flare and irreversible joint damage.
